US Bancorp’s Cytek Biosciences CTKB Stock Holding History

US Bancorp’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.43K	Buy	557 +103	+23%	+$486	﹤0.01%	3762
2025 Q4	$2.29K	Hold	454	–	–	﹤0.01%	3735
2025 Q3	$1.57K	Sell	454 -17,354	-97%	-$65.1K	﹤0.01%	3783
2025 Q2	$60.5K	Buy	17,808 +7,128	+67%	+$23.8K	﹤0.01%	2685
2025 Q1	$42.8K	Buy	10,680 +10,571	+9,698%	+$54.8K	﹤0.01%	2824
2024 Q4	$707	Sell	109 -891	-89%	-$5.31K	﹤0.01%	4000
2024 Q3	$5.54K	Buy	+1,000	New	+$5.67K	﹤0.01%	3538
2021 Q4	–	Sell	-320	Closed	-$7K	–	4112
2021 Q3	$7K	Buy	+320	New	+$7.53K	﹤0.01%	3548

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

US Bancorp's CTKB Position: Q1 2026 in Review

US Bancorp increased its Cytek Biosciences (CTKB) stake by 23% in Q1 2026, buying an estimated $486 and bringing the position to 557 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

US Bancorp first reported a position in CTKB in Q3 2021 and has held it in 8 quarters since. The position peaked at $60.5K in Q2 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

US Bancorp held 557 shares of Cytek Biosciences worth $2.43K as of Q1 2026.
US Bancorp bought 103 Cytek Biosciences shares in Q1 2026, an estimated $486.
Cytek Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3762 holding.
US Bancorp first reported a position in Cytek Biosciences in Q3 2021 and has held it in 8 quarters since.
US Bancorp's Cytek Biosciences position peaked at $60.5K in Q2 2025.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.